Applied Biologics Completes Trial Sentinel Enrollment
The Phase 3 BIOxHEAL study for chronic diabetic foot ulcers moves toward an independent safety review before randomized enrollment begins.
Updated on Nov. 4, 2026 in Diabetes
Applied Biologics has completed enrollment of the sentinel safety cohort in its Phase 3 randomized controlled trial evaluating BIOxHEAL in patients with chronic, nonhealing diabetic foot ulcers. The company will not advance to randomized enrollment until an independent Data and Safety Monitoring Board review and FDA authorization are complete.
Why it matters
Diabetic foot ulcers can be slow to heal and are a serious complication of diabetes, so a topical biologic with a defined 12-week wound-closure endpoint is being tested in a controlled setting. The sentinel cohort is a required safety checkpoint before the larger randomized phase of the study can proceed.
The Phase 3 study plans 243 randomized participants across up to 30 sites, with a 2:1 allocation to BIOxHEAL plus standard of care versus standard of care alone. Its primary endpoint is complete closure of target ulcers at 12 weeks, and no efficacy results have yet been reported.
The players
Applied Biologics
Applied Biologics is the company developing BIOxHEAL, a human amniotic membrane-derived topical biologic, and sponsoring the Phase 3 trial.
Data and Safety Monitoring Board
The Data and Safety Monitoring Board is an independent expert panel that reviews accumulating safety data in clinical trials and advises whether they may proceed.
The details
Applied Biologics announced that all participants in the sentinel cohort receive BIOxHEAL plus standard of care, a sterile, single-use, topically applied biologic derived from human amniotic membrane. The trial is multicenter, open-label and randomized, with Professional Education and Research Institute serving as the clinical research organization.
Timeline
Nov. 4, 2026: Applied Biologics announces completion of sentinel cohort enrollment.
In the coming weeks: The Data and Safety Monitoring Board is expected to review sentinel cohort safety data and issue a recommendation.
After DSMB recommendation and FDA authorization: Randomized enrollment is expected to begin.
12 weeks after enrollment: Primary endpoint of complete wound closure is measured.
Health Landscape
Phase 3 trials of advanced wound biologics for diabetic foot ulcers follow the same staged safety-review model that governs most FDA-regulated investigational products. This sentinel-cohort step reflects the protocol structure applied to randomized trials of this kind.
For people living with chronic diabetic foot ulcers, this trial offers a possible new topical treatment option that is not yet available outside a clinical study. Participation would depend on eligibility and enrollment at one of the up to 30 investigational sites.
The takeaway
Trial participation remains a path for patients with hard-to-heal diabetic foot ulcers while safety data is reviewed. Readers should consult their clinicians about whether a study may be appropriate for them.
What happens next
The DSMB is expected to review sentinel cohort safety data in the coming weeks, after which randomized enrollment may begin pending FDA authorization.
Further reading
Explore more on Diabetes research and treatment developments.
Source note: This article includes information reported by The Manila times.
